BioSpace News Archive

AstraZeneca and Merck’s LYNPARZA Added to Bevacizumab Reduced the Risk of Disease Progression or Death by 41% in the Overall Trial Population of Women Who Responded to Platinum-Based Chemotherapy

Zymeworks Inc. announced updated data from the ongoing multi-center Phase 1 clinical trial evaluating ZW25 in patients with HER2‑expressing solid tumors, including biliary tract cancer, colorectal cancer, gynecological cancers, and gastroesophageal adenocarcinoma, in a poster discussion presentation at the ESMO 2019 Congress, taking place September 27 - October 1 in Barcelona, Spain.

Independent analysis of LUTONIX® 035 Drug Coated Balloon patient-level data showed no statistically significant mortality increase

AstraZeneca presented detailed overall survival (OS) results from the Phase III FLAURA trial of TAGRISSO® (osimertinib) in the 1st-line treatment of adult patients with locally-advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).

Study Met Outcomes for Safety and 71 Percent of Patients with Locally Advanced or Metastatic Urothelial (Bladder) Cancer Had a Confirmed Response

Bristol-Myers Squibb Company announced five-year results from the Phase 3 CheckMate -067 clinical trial, which continues to demonstrate improved overall survival with the first-line combination of Opdivo (nivolumab) plus Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced metastatic melanoma.

GRAIL, Inc. announced that new data supporting its technology to detect cancer at early stages with a single blood test will be presented as a late-breaking oral presentation at the European Society for Medical Oncology 2019 Congress in Barcelona, Spain.

Data presented at ESMO 2019 support initiation of phase II/III registrational trial with pembrolizumab in first-line recurrent/metastatic HNSCC

Early phase study of BPM31510 demonstrates BERG’s Interrogative Biology® platform can identify the molecular basis of efficacy and adverse events, offering critical insights for drug late-stage development from analyses of longitudinal patient samples

Forbius reported results from its non-clinical GLP toxicology program with first-in-class selective TGF-beta inhibitor AVID200 and evidence of TGF-beta target engagement in patients treated with this novel immuno-oncology agent at the European Society of Medical Oncology 2019 Annual Congress in Barcelona.